ReviewNature reviews. Endocrinology2017
'Omics' and endocrine-disrupting chemicals - new paths forward.
Review in Nature reviews. Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Genetic Regulation of DNA Methylation and Its Mediating Role in Blood Pressure: A Genome-Wide Twin Study.MedComm · 2026Article
- Genetic variations interact with polybrominated diphenyl ether exposure to alter lipid homeostasis.Nature communications · 2026Article
- Vinclozolin and MEHP disrupt piRNA and miRNA expression and increase apoptosis in embryonic mouse ovaries.Scientific reports · 2025Article
- Endocrine-disrupting chemicals and female reproductive health: a growing concern.Nature reviews. Endocrinology · 2025Review
- Unraveling the Core of Endometriosis: The Impact of Endocrine Disruptors.International journal of molecular sciences · 2025Review
- Impact of endocrine disrupting chemicals (EDCs) on epigenetic regulation in the uterus: a narrative review.Reproductive biology and endocrinology : RB&E · 2025Review
- Adipose tissue as target of environmental toxicants: focus on mitochondrial dysfunction and oxidative inflammation in metabolic dysfunction-associated steatotic liver disease.Molecular and cellular biochemistry · 2025Review
- Article
- Vitamin D Deficiency Exacerbates Poor Sleep Outcomes with Endocrine-Disrupting Chemicals Exposure: A Large American Population Study.Nutrients · 2024Article
- Review
- Southeast Asia's environmental challenges: emergence of new contaminants and advancements in testing methods.Frontiers in toxicology · 2024Review
- Prenatal exposures to endocrine disrupting chemicals: The role of multi-omics in understanding toxicity.Molecular and cellular endocrinology · 2023Review
- Prenatal Exposure to Metabolism-Disrupting Chemicals, Cord Blood Transcriptome Perturbations, and Birth Weight in a Belgian Birth Cohort.International journal of molecular sciences · 2023Article
- Investigating the relationship between non-occupational pesticide exposure and metabolomic biomarkers.Frontiers in public health · 2023Article
- Trends in metabolic dysfunction in polycystic ovary syndrome: a bibliometric analysis.Frontiers in endocrinology · 2023Review
- Endocrine Disrupting Chemicals' Effects in Children: What We Know and What We Need to Learn?International journal of molecular sciences · 2022Review
- Review
- Advancing precision public health using human genomics: examples from the field and future research opportunities.Genome medicine · 2021Article
- Hallmarks of environmental insults.Cell · 2021Review
- Exposome-wide Association Study for Metabolic Syndrome.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The emerging field of omics - large-scale data-rich biological measurements of the genome - provides new opportunities to advance and strengthen research into endocrine-disrupting chemicals (EDCs). Although some EDCs have been associated with adverse health effects in humans, our understanding of their impact remains incomplete. Progress in the field has been primarily limited by our inability to adequately estimate and characterize exposure and identify sensitive and measurable outcomes during windows of vulnerability. Evolving omics technologies in genomics, epigenomics and mitochondriomics have the potential to generate data that enhance exposure assessment to include the exposome - the totality of the lifetime exposure burden - and provide biology-based estimates of individual risks. Applying omics technologies to expand our knowledge of individual risk and susceptibility will augment biological data in the prediction of variability and response to disease, thereby further advancing EDC research. Together, refined exposure characterization and enhanced disease-risk prediction will help to bridge crucial gaps in EDC research and create opportunities to move the field towards a new vision - precision public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.